• Oculis will present Phase 2 ACUITY results for privosegtor in acute optic neuritis at the CNS Summit on November 2–3, 2026.
• The trial showed improved visual function, preservation of retinal anatomy and reduced blood neurofilament levels.
• Positive findings supported FDA Breakthrough Therapy designation and European Medicines Agency PRIME designation for privosegtor in optic neuritis.
• The PIONEER-1 registrational trial is enrolling patients with acute-onset optic neuritis, including those with or without multiple sclerosis.
• The company also expects investigational new drug application clearance for treating acute multiple sclerosis relapses in the fourth quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oculis Holding AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610290510OMX_____CNEWS_EN_GNW1001280610_en) on October 29, 2026, and is solely responsible for the information contained therein.